1	Xenogeneic	xenogeneic	_	_	_	_	_	_	_
2	human	human	_	_	_	_	_	_	_
3	serum	serum	_	_	_	_	_	_	_
4	promotes	promote	_	_	_	_	_	_	_
5	leukocyte	leukocyte	_	_	_	_	_	_	_
6	adhesion	adhesion	_	_	_	_	_	_	_
7	to	to	_	_	_	_	_	_	_
8	porcine	porcine	_	_	_	_	_	_	_
9	endothelium	endothelium	_	_	_	_	_	_	_
10	under	under	_	_	_	_	_	_	_
11	flow	flow	_	_	_	_	_	_	_
12	conditions	condition	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	possibly	possibly	_	_	_	_	_	_	_
15	through	through	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	activation	activation	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	the	the	_	_	_	_	_	_	_
20	transcription	transcription	_	_	_	_	_	_	_
21	factor	factor	_	_	_	_	_	_	_
22	NF-kappa	NF-kappa	_	_	_	_	_	_	_
23	B.	B.	_	_	_	_	_	_	_
24	Endothelial	endothelial	_	_	_	_	_	_	_
25	cell	cell	_	_	_	_	_	_	_
26	activation	activation	_	_	_	_	_	_	_
27	and	and	_	_	_	_	_	_	_
28	leukocyte	leukocyte	_	_	_	_	_	_	_
29	infiltration	infiltration	_	_	_	_	_	_	_
30	are	be	_	_	_	_	_	_	_
31	a	a	_	_	_	_	_	_	_
32	consistent	consistent	_	_	_	_	_	_	_
33	feature	feature	_	_	_	_	_	_	_
34	of	of	_	_	_	_	_	_	_
35	discordant	discordant	_	_	_	_	_	_	_
36	xenograft	xenograft	_	_	_	_	_	_	_
37	rejection	rejection	_	_	_	_	_	_	_
38	.	.	_	_	_	_	_	_	_

1	Here	here	_	_	_	_	_	_	_
2	we	we	_	_	_	_	_	_	_
3	evaluated	evaluate	_	_	_	_	_	_	_
4	whether	whether	_	_	_	_	_	_	_
5	xenogeneic	xenogeneic	_	_	_	_	_	_	_
6	serum	serum	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	as	as	_	_	_	_	_	_	_
9	a	a	_	_	_	_	_	_	_
10	source	source	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	xenoreactive	xenoreactive	_	_	_	_	_	_	_
13	natural	natural	_	_	_	_	_	_	_
14	antibodies	antibody	_	_	_	_	_	_	_
15	and	and	_	_	_	_	_	_	_
16	complement	complement	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	induced	induce	_	_	_	_	_	_	_
19	endothelial	endothelial	_	_	_	_	_	_	_
20	cell	cell	_	_	_	_	_	_	_
21	activation	activation	_	_	_	_	_	_	_
22	with	with	_	_	_	_	_	_	_
23	consequent	consequent	_	_	_	_	_	_	_
24	leukocyte	leukocyte	_	_	_	_	_	_	_
25	adhesion	adhesion	_	_	_	_	_	_	_
26	under	under	_	_	_	_	_	_	_
27	flow	flow	_	_	_	_	_	_	_
28	conditions	condition	_	_	_	_	_	_	_
29	.	.	_	_	_	_	_	_	_

1	Porcine	porcine	_	_	_	_	_	_	_
2	aortic	aortic	_	_	_	_	_	_	_
3	endothelial	endothelial	_	_	_	_	_	_	_
4	cells	cell	_	_	_	_	_	_	_
5	(	(	_	_	_	_	_	_	_
6	PAEC	PAEC	_	_	_	_	_	_	_
7	)	)	_	_	_	_	_	_	_
8	were	be	_	_	_	_	_	_	_
9	incubated	incubate	_	_	_	_	_	_	_
10	for	for	_	_	_	_	_	_	_
11	1	1	_	_	_	_	_	_	_
12	hr	hr	_	_	_	_	_	_	_
13	30	30	_	_	_	_	_	_	_
14	min	min	_	_	_	_	_	_	_
15	or	or	_	_	_	_	_	_	_
16	5	5	_	_	_	_	_	_	_
17	hr	hr	_	_	_	_	_	_	_
18	with	with	_	_	_	_	_	_	_
19	10	10	_	_	_	_	_	_	_
20	%	%	_	_	_	_	_	_	_
21	homologous	homologous	_	_	_	_	_	_	_
22	porcine	porcine	_	_	_	_	_	_	_
23	serum	serum	_	_	_	_	_	_	_
24	(	(	_	_	_	_	_	_	_
25	control	control	_	_	_	_	_	_	_
26	)	)	_	_	_	_	_	_	_
27	or	or	_	_	_	_	_	_	_
28	10	10	_	_	_	_	_	_	_
29	%	%	_	_	_	_	_	_	_
30	xenogeneic	xenogeneic	_	_	_	_	_	_	_
31	human	human	_	_	_	_	_	_	_
32	serum	serum	_	_	_	_	_	_	_
33	and	and	_	_	_	_	_	_	_
34	then	then	_	_	_	_	_	_	_
35	perfused	perfuse	_	_	_	_	_	_	_
36	with	with	_	_	_	_	_	_	_
37	total	total	_	_	_	_	_	_	_
38	human	human	_	_	_	_	_	_	_
39	leukocytes	leukocyte	_	_	_	_	_	_	_
40	in	in	_	_	_	_	_	_	_
41	a	a	_	_	_	_	_	_	_
42	parallel	parallel	_	_	_	_	_	_	_
43	plate	plate	_	_	_	_	_	_	_
44	flow	flow	_	_	_	_	_	_	_
45	chamber	chamber	_	_	_	_	_	_	_
46	under	under	_	_	_	_	_	_	_
47	laminar	laminar	_	_	_	_	_	_	_
48	flow	flow	_	_	_	_	_	_	_
49	(	(	_	_	_	_	_	_	_
50	1.5	1.5	_	_	_	_	_	_	_
51	dynes/cm2	dynes/cm2	_	_	_	_	_	_	_
52	)	)	_	_	_	_	_	_	_
53	.	.	_	_	_	_	_	_	_

1	Adherent	adherent	_	_	_	_	_	_	_
2	cells	cell	_	_	_	_	_	_	_
3	were	be	_	_	_	_	_	_	_
4	counted	count	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	digital	digital	_	_	_	_	_	_	_
7	image	image	_	_	_	_	_	_	_
8	analysis	analysis	_	_	_	_	_	_	_
9	.	.	_	_	_	_	_	_	_

1	Xenogeneic	xenogeneic	_	_	_	_	_	_	_
2	human	human	_	_	_	_	_	_	_
3	serum	serum	_	_	_	_	_	_	_
4	significantly	significantly	_	_	_	_	_	_	_
5	(	(	_	_	_	_	_	_	_
6	P	p	_	_	_	_	_	_	_
7	<	<	_	_	_	_	_	_	_
8	0.01	0.01	_	_	_	_	_	_	_
9	)	)	_	_	_	_	_	_	_
10	increased	increase	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	number	number	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	adherent	adherent	_	_	_	_	_	_	_
15	leukocytes	leukocyte	_	_	_	_	_	_	_
16	as	as	_	_	_	_	_	_	_
17	compared	compare	_	_	_	_	_	_	_
18	with	with	_	_	_	_	_	_	_
19	porcine	porcine	_	_	_	_	_	_	_
20	serum	serum	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	A	a	_	_	_	_	_	_	_
2	similar	similar	_	_	_	_	_	_	_
3	adhesive	adhesive	_	_	_	_	_	_	_
4	response	response	_	_	_	_	_	_	_
5	was	be	_	_	_	_	_	_	_
6	elicited	elicit	_	_	_	_	_	_	_
7	by	by	_	_	_	_	_	_	_
8	TNF	TNF	_	_	_	_	_	_	_
9	alpha	alpha	_	_	_	_	_	_	_
10	(	(	_	_	_	_	_	_	_
11	100	100	_	_	_	_	_	_	_
12	U/ml	U/ml	_	_	_	_	_	_	_
13	)	)	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	one	one	_	_	_	_	_	_	_
16	of	of	_	_	_	_	_	_	_
17	the	the	_	_	_	_	_	_	_
18	most	most	_	_	_	_	_	_	_
19	potent	potent	_	_	_	_	_	_	_
20	inducers	inducer	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	endothelial	endothelial	_	_	_	_	_	_	_
23	cell	cell	_	_	_	_	_	_	_
24	adhesive	adhesive	_	_	_	_	_	_	_
25	properties	property	_	_	_	_	_	_	_
26	,	,	_	_	_	_	_	_	_
27	here	here	_	_	_	_	_	_	_
28	used	use	_	_	_	_	_	_	_
29	as	as	_	_	_	_	_	_	_
30	positive	positive	_	_	_	_	_	_	_
31	control	control	_	_	_	_	_	_	_
32	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	order	order	_	_	_	_	_	_	_
3	to	to	_	_	_	_	_	_	_
4	elucidate	elucidate	_	_	_	_	_	_	_
5	possible	possible	_	_	_	_	_	_	_
6	mechanisms	mechanism	_	_	_	_	_	_	_
7	underlying	underlie	_	_	_	_	_	_	_
8	endothelial	endothelial	_	_	_	_	_	_	_
9	cell	cell	_	_	_	_	_	_	_
10	activation	activation	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	xenogeneic	xenogeneic	_	_	_	_	_	_	_
13	serum	serum	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	we	we	_	_	_	_	_	_	_
16	focussed	focusse	_	_	_	_	_	_	_
17	on	on	_	_	_	_	_	_	_
18	transcription	transcription	_	_	_	_	_	_	_
19	factor	factor	_	_	_	_	_	_	_
20	NF-kappa	NF-kappa	_	_	_	_	_	_	_
21	B	B	_	_	_	_	_	_	_
22	,	,	_	_	_	_	_	_	_
23	a	a	_	_	_	_	_	_	_
24	central	central	_	_	_	_	_	_	_
25	regulator	regulator	_	_	_	_	_	_	_
26	for	for	_	_	_	_	_	_	_
27	the	the	_	_	_	_	_	_	_
28	induction	induction	_	_	_	_	_	_	_
29	of	of	_	_	_	_	_	_	_
30	different	different	_	_	_	_	_	_	_
31	genes	gene	_	_	_	_	_	_	_
32	,	,	_	_	_	_	_	_	_
33	including	include	_	_	_	_	_	_	_
34	adhesive	adhesive	_	_	_	_	_	_	_
35	molecules	molecule	_	_	_	_	_	_	_
36	and	and	_	_	_	_	_	_	_
37	chemoattractants	chemoattractant	_	_	_	_	_	_	_
38	.	.	_	_	_	_	_	_	_

1	By	by	_	_	_	_	_	_	_
2	confocal	confocal	_	_	_	_	_	_	_
3	fluorescence	fluorescence	_	_	_	_	_	_	_
4	microscopy	microscopy	_	_	_	_	_	_	_
5	,	,	_	_	_	_	_	_	_
6	we	we	_	_	_	_	_	_	_
7	observed	observe	_	_	_	_	_	_	_
8	a	a	_	_	_	_	_	_	_
9	positive	positive	_	_	_	_	_	_	_
10	staining	staining	_	_	_	_	_	_	_
11	for	for	_	_	_	_	_	_	_
12	NF-kappa	NF-kappa	_	_	_	_	_	_	_
13	B	B	_	_	_	_	_	_	_
14	(	(	_	_	_	_	_	_	_
15	p65	p65	_	_	_	_	_	_	_
16	subunit	subunit	_	_	_	_	_	_	_
17	)	)	_	_	_	_	_	_	_
18	in	in	_	_	_	_	_	_	_
19	the	the	_	_	_	_	_	_	_
20	nuclei	nucleus	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	PAEC	PAEC	_	_	_	_	_	_	_
23	exposed	expose	_	_	_	_	_	_	_
24	for	for	_	_	_	_	_	_	_
25	1	1	_	_	_	_	_	_	_
26	hr	hr	_	_	_	_	_	_	_
27	30	30	_	_	_	_	_	_	_
28	min	min	_	_	_	_	_	_	_
29	to	to	_	_	_	_	_	_	_
30	human	human	_	_	_	_	_	_	_
31	serum	serum	_	_	_	_	_	_	_
32	,	,	_	_	_	_	_	_	_
33	which	which	_	_	_	_	_	_	_
34	indicated	indicate	_	_	_	_	_	_	_
35	NF-kappa	NF-kappa	_	_	_	_	_	_	_
36	B	B	_	_	_	_	_	_	_
37	activation	activation	_	_	_	_	_	_	_
38	in	in	_	_	_	_	_	_	_
39	this	this	_	_	_	_	_	_	_
40	setting	setting	_	_	_	_	_	_	_
41	.	.	_	_	_	_	_	_	_

1	At	at	_	_	_	_	_	_	_
2	variance	variance	_	_	_	_	_	_	_
3	,	,	_	_	_	_	_	_	_
4	in	in	_	_	_	_	_	_	_
5	PAEC	PAEC	_	_	_	_	_	_	_
6	incubated	incubate	_	_	_	_	_	_	_
7	with	with	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	homologous	homologous	_	_	_	_	_	_	_
10	serum	serum	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	NF-kappa	NF-kappa	_	_	_	_	_	_	_
13	B	B	_	_	_	_	_	_	_
14	was	be	_	_	_	_	_	_	_
15	strictly	strictly	_	_	_	_	_	_	_
16	localized	localize	_	_	_	_	_	_	_
17	in	in	_	_	_	_	_	_	_
18	the	the	_	_	_	_	_	_	_
19	cell	cell	_	_	_	_	_	_	_
20	cytoplasm	cytoplasm	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	Treatment	Treatment	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	PAEC	PAEC	_	_	_	_	_	_	_
4	exposed	expose	_	_	_	_	_	_	_
5	to	to	_	_	_	_	_	_	_
6	xenogeneic	xenogeneic	_	_	_	_	_	_	_
7	serum	serum	_	_	_	_	_	_	_
8	with	with	_	_	_	_	_	_	_
9	the	the	_	_	_	_	_	_	_
10	NF-kappa	NF-kappa	_	_	_	_	_	_	_
11	B	B	_	_	_	_	_	_	_
12	inhibitors	inhibitor	_	_	_	_	_	_	_
13	pyrrolidinedithiocarbamate	pyrrolidinedithiocarbamate	_	_	_	_	_	_	_
14	(	(	_	_	_	_	_	_	_
15	PDTC	PDTC	_	_	_	_	_	_	_
16	,	,	_	_	_	_	_	_	_
17	25	25	_	_	_	_	_	_	_
18	microM	microm	_	_	_	_	_	_	_
19	)	)	_	_	_	_	_	_	_
20	and	and	_	_	_	_	_	_	_
21	tosyl-phechloromethylketone	tosyl-phechloromethylketone	_	_	_	_	_	_	_
22	(	(	_	_	_	_	_	_	_
23	TPCK	TPCK	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	25	25	_	_	_	_	_	_	_
26	microM	microM	_	_	_	_	_	_	_
27	)	)	_	_	_	_	_	_	_
28	significantly	significantly	_	_	_	_	_	_	_
29	(	(	_	_	_	_	_	_	_
30	P	p	_	_	_	_	_	_	_
31	<	<	_	_	_	_	_	_	_
32	0.01	0.01	_	_	_	_	_	_	_
33	)	)	_	_	_	_	_	_	_
34	reduced	reduce	_	_	_	_	_	_	_
35	leukocyte	leukocyte	_	_	_	_	_	_	_
36	adhesion	adhesion	_	_	_	_	_	_	_
37	in	in	_	_	_	_	_	_	_
38	respect	respect	_	_	_	_	_	_	_
39	to	to	_	_	_	_	_	_	_
40	PAEC	PAEC	_	_	_	_	_	_	_
41	treated	treat	_	_	_	_	_	_	_
42	with	with	_	_	_	_	_	_	_
43	human	human	_	_	_	_	_	_	_
44	serum	serum	_	_	_	_	_	_	_
45	alone	alone	_	_	_	_	_	_	_
46	.	.	_	_	_	_	_	_	_

1	Findings	finding	_	_	_	_	_	_	_
2	that	that	_	_	_	_	_	_	_
3	xenogeneic	xenogeneic	_	_	_	_	_	_	_
4	serum	serum	_	_	_	_	_	_	_
5	promotes	promote	_	_	_	_	_	_	_
6	leukocyte-endothelium	leukocyte-endothelium	_	_	_	_	_	_	_
7	interaction	interaction	_	_	_	_	_	_	_
8	possibly	possibly	_	_	_	_	_	_	_
9	through	through	_	_	_	_	_	_	_
10	NF-kappa	NF-kappa	_	_	_	_	_	_	_
11	B	B	_	_	_	_	_	_	_
12	activation	activation	_	_	_	_	_	_	_
13	might	might	_	_	_	_	_	_	_
14	be	be	_	_	_	_	_	_	_
15	relevant	relevant	_	_	_	_	_	_	_
16	for	for	_	_	_	_	_	_	_
17	designing	design	_	_	_	_	_	_	_
18	future	future	_	_	_	_	_	_	_
19	therapeutic	therapeutic	_	_	_	_	_	_	_
20	strategies	strategy	_	_	_	_	_	_	_
21	aimed	aim	_	_	_	_	_	_	_
22	at	at	_	_	_	_	_	_	_
23	prolonging	prolong	_	_	_	_	_	_	_
24	xenograft	xenograft	_	_	_	_	_	_	_
25	survival	survival	_	_	_	_	_	_	_
26	.	.	_	_	_	_	_	_	_

